An Investigation on the Distribution of Bacteria Isolation in a Grade A Hospital in Ganzi Tibetan Prefecture and the Resistance to Antibacterial Drugs in Common Use
CHEN Shanshan, DUAN Fengmei, DANZHEN Zhuoma, et al
The People's Hospital of Ganzi Tibetan Autonomous Prefecture, Tibet Ganzi Kangding 626000, China
Abstract：Objective: To investigate the distribution of bacteria isolation in a grade A hospital in Ganzi Tibetan Prefecture, and analyze the resistance to commonly used antibacterial drugs. Methods: The clinically isolated strains between 2017 and 2020 were collected and analyzed from perspectives of specimen source, detection of bacteria, and drug sensitivity test results. Results: A total of 2,946 non-repetitive strains were isolated, most of which were from ICU, department of gastrointestinal surgery, department of hepatobiliary surgery, department of neurosurgery, department of orthopedics, and department of urology. Gram-positive bacteria and gram-negative bacteria accounted for 31.40% and 68.60%, mainly including Escherichia coli, Klebsiella pneumoniae, and staphylococcus aureus. Escherichia coli and Klebsiella pneumoniae were highly sensitive to carbapenems, and the drug resistance rates of most bacteria were lower than 10%. Staphylococcus aureus and staphylococcus epidermidis were highly resistant to penicillin G, followed by erythromycin. No vancomycin or linezolid-resistant staphylococcus aureus was detected. 1,068 (36.25%) extended-spectrum β-lactamase (ESBLs) strains, 159 (5.40%) strains of methicillin-resistant staphylococcus (MRS), and 248 (8.42%) strains of methicillin-resistant staphylococcus aureus (MRSA), and 2 (0.07%) strains of vancomycin-resistant enterococcus (VRE) were detected. MRS and MRA both were completely resistant to penicillin G and oxacillin, but sensitive to vancomycin, teicoplanin, linezolid, and sulfamethoxazole/trimethoprim. Conclusion: Escherichia coli, Klebsiella pneumoniae, and staphylococcus aureus were main bacteria isolated in a grade A hospitals in Ganzi Tibetan Prefecture from 2017 to 2020. ESBLs. MRS, MRSA and VRE were detected, with drug resistance. Therefore, antibacterial drugs are recommended to be used rationally.
陈姗姗, 段凤梅, 单珍卓玛, 张垚. 甘孜藏区某三甲医院分离细菌分布现状及对常用抗菌药物的耐药性分析[J]. 河北医学, 2022, 28(2): 308-313.
CHEN Shanshan, DUAN Fengmei, DANZHEN Zhuoma, et al. An Investigation on the Distribution of Bacteria Isolation in a Grade A Hospital in Ganzi Tibetan Prefecture and the Resistance to Antibacterial Drugs in Common Use. HeBei Med, 2022, 28(2): 308-313.
[1] 陈雯,张立平,梁沛枫,等.某三级综合医院2017年度细菌耐药性监测分析[J].中华医院感染学杂志,2019,29(23):3521~3525. [2] Denisuik AJ,Karlowsky JA,Adam HJ,et al.Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in canadian hospital laboratories from 2007 to 2016[J].Antimicrob Chemother,2019,74(4):64~71. [3] 赵新惠,刘敏,王建,等.滨州市中心医院抗生素的使用情况及感染病原菌和细菌耐药性的调查分析[J].中国临床实用医学,2021,12(1):61~64. [4] 尚红,王毓三,申子瑜,等.全国临床检验操作规程[M].第4版.北京,人民卫生出版社,2015.629~631. [5] Wayne P A.Clinical and Laborarory Standards Institute (CLSI).Performance standards for antimicrobial susceptibility testing[M].Twenty-seventh informatiol supplement,2017.100. [6] 张曼,牟霞,徐艳,等.某医院2014年至2017年临床分离病原菌种类分布及其耐药性变化分析[J].中国消毒学杂志,2019,36(1):41~43,46. [7] 赵丽娜,张险峰,朱琼芳,等.苏州市某三甲医院2017年临床分离菌耐药性监测[J].中国消毒学杂志,2020,37(1):33~36. [8] 范晓蓓,李莲,梁荣鑫,等.某医院2017年至2019年大肠埃希菌的临床分布及耐药性分析[J].湖北医药学院学报,2021,40(2):168~172. [9] 孙菡,文武,蹇贻.2014年至2019年大肠埃希菌感染流行病学调查及耐药性分析[J].公共卫生与预防医学,2021,32(1):55~58. [10] Tomczyk S,Zanichelli V,Grayson ML,et al.Control of carbapenem-resistant enterobacteriaceae,acinetobacter baumannii,and pseudomonas aeruginosa in healthcare facilities:a systematic review and reanalysis of quasi-experimental studies[J].Clin Infect Dis,2019,68(5):873~884. [11] 陈培培,管婧,麦颖,等.2015-2017年广东某医院细菌耐药性监测结果分析[J].中国感染与化疗杂志,2019,19(1):71~77. [12] 胡志军,潘恺,潘晓龙,等.2017年安徽省某三甲医院细菌耐药性监测[J].中国抗生素杂志,2019,44(2):248~253. [13] Yin D,Wu S,Yang Y,et al.Results from the China antimicrobial surveillance network (chinet) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of enterobacteriaceae and pseudomonas aeruginosa[J].Antimicrob Agents Chemother,2019,63(4):e2431~e2418.
2022, Vol. 28 
冀公网安备13080202000786号